ライフサイエンスコーパス: peginterferon alfa-2a

1 for standard-dose peginterferon alfa-2b vs. peginterferon alfa-2a).

2 HCV when dosed alone or in combination with peginterferon alfa-2a.

3 -associated Kaposi sarcoma were treated with peginterferon alfa-2a.

4 ed volunteers were treated for 12 weeks with peginterferon alfa-2a.

5 lfa-2b, and 31.5% (95% CI, 27.9 to 35.2) for peginterferon alfa-2a.

6 ween standard-dose peginterferon alfa-2b and peginterferon alfa-2a.

7 Patients were retreated with peginterferon alfa-2a 180 microg/wk plus ribavirin 1000-

8 aily for 8 weeks followed by the addition of peginterferon alfa-2a 180 ug/week to entecavir for an ad

9 n therapy are not significantly higher using peginterferon alfa 2a (180 microg/wk; 43%) or peginterfe

10 eive simeprevir (150 mg once daily, orally), peginterferon alfa 2a (180 mug once weekly, subcutaneous

11 then 750 mg every 8 hours) for 12 weeks and peginterferon alfa-2a (180 microg per week) and ribaviri

12 ntrol group (called the PR48 group) received peginterferon alfa-2a (180 microg per week) and ribaviri

13 y assigned to receive one of three regimens: peginterferon alfa-2a (180 microg per week) plus ribavir

14 included nitazoxanide (500 mg) twice daily, peginterferon alfa-2a (180 microg) once weekly, and weig

15 ients randomized to the conventional dose of peginterferon alfa-2a (180 microg/week) for the pairwise

16 interferon +/- ribavirin were retreated with peginterferon alfa-2a (180 microg/wk) and ribavirin (100

17 (HCV) genotype 1 infection were treated with peginterferon alfa-2a (180 microg/wk) and ribavirin (100

18 irtide at a daily dose of 2 mg or 10 mg plus peginterferon alfa-2a (180 mug per week) for 48 weeks, f

19 f 0.015 mg/kg (0.5 mg maximum) for 48 weeks; peginterferon alfa-2a (180 ug/1.73m(2) subcutaneously) o

20 Patients randomized to the highest doses of peginterferon alfa-2a (270 microg/week) and ribavirin (1

21 Higher fixed doses of peginterferon alfa-2a (270 microg/week) and ribavirin (1

22 Among patients receiving peginterferon alfa-2a (270 microg/week) the magnitude of

23 During treatment, patients receiving peginterferon alfa-2a (40 kd) had statistically signific

24 e of sustained virological response (SVR) to peginterferon alfa-2a (40 kd) in combination with ribavi

25 open-label, randomized studies that compared peginterferon alfa-2a (40 kd) with interferon alfa-2a.

26 otent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these pa

27 ith polyethylene glycol-modified interferon (peginterferon) alfa-2a (40 kd) provides improved sustain

28 in which patients received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by

29 se of HALT-C trial were randomized to either peginterferon alfa-2a (90 microg/week) maintenance thera

30 al, we randomly assigned patients to receive peginterferon alfa-2a alone (180 mug per week) for 48 we

31 irin (56 percent vs. 44 percent, P<0.001) or peginterferon alfa-2a alone (56 percent vs. 29 percent,

32 irin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of

33 Treatment with peginterferon alfa-2a alone produces significantly highe

34 A total of 24 patients received peginterferon alfa-2a alone, 50 received 2 mg and 50 rec

35 ed with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone.

36 Simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in

37 bination therapy with pegylated interferons (peginterferon alfa-2a and alfa-2b) yields an adverse eve

38 Synergy was observed between R1626 and peginterferon alfa-2a and between R1626 and ribavirin.

39 erant (IT) children and adults with combined peginterferon alfa-2a and entecavir results in a decline

40 8 hours thereafter) for 12 weeks, as well as peginterferon alfa-2a and ribavirin (at the same doses a

41 daily) alone (Group A, 11 patients) or with peginterferon alfa-2a and ribavirin (Group B, 10 patient

42 group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patient

43 were randomized 2:1:1 to receive 48 weeks of peginterferon alfa-2a and ribavirin (PegIFN/RBV) in comb

44 ty of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs

45 essed virologic response to retreatment with peginterferon alfa-2a and ribavirin (RBV), as a function

46 or 12 weeks; patients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks i

47 bavirin for 12 weeks followed by 36 weeks of peginterferon alfa-2a and ribavirin alone.

48 rin was more effective than retreatment with peginterferon alfa-2a and ribavirin alone.

49 previous null responders with simeprevir and peginterferon alfa-2a and ribavirin and telaprevir and p

50 of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy

51 : a group receiving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR

52 vir placebo (once a day) in combination with peginterferon alfa-2a and ribavirin for 12 weeks followe

53 mg twice daily or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patien

54 Nonresponders with HCV genotype 1 were given peginterferon alfa-2a and ribavirin for 2 weeks (course

55 responders to interferon were retreated with peginterferon alfa-2a and ribavirin for 24 (n=177) or 48

56 y for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a and ribavirin for 36 weeks (n = 28

57 group, receiving telaprevir for 24 weeks and peginterferon alfa-2a and ribavirin for 48 weeks (at the

58 ts to the PR48 (or control) group, receiving peginterferon alfa-2a and ribavirin for 48 weeks (at the

59 to groups that were given standard of care (peginterferon alfa-2a and ribavirin for 48 weeks, n = 40

60 , all 10 (100%) who received sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks had a su

61 monotherapy for 12 weeks or sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks.

62 ribavirin was non-inferior to telaprevir and peginterferon alfa-2a and ribavirin for SVR12 (54% [203/

63 istered a 12-week regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin in 327 patients with

64 designed to test the efficacy and safety of peginterferon alfa-2a and ribavirin in children, provide

65 to HCV genotype 1 who underwent therapy with peginterferon alfa-2a and ribavirin in the Study of Vira

66 fferent dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway.

67 Peginterferon alfa-2a and ribavirin therapy provides goo

68 ron alfa-2a and ribavirin and telaprevir and peginterferon alfa-2a and ribavirin treatment, respectiv

69 nders during at least one previous course of peginterferon alfa-2a and ribavirin treatment.

70 The efficacy of high-dose regimens of peginterferon alfa-2a and ribavirin was compared with co

71 reatment with telaprevir in combination with peginterferon alfa-2a and ribavirin was more effective t

72 Simeprevir and peginterferon alfa-2a and ribavirin was non-inferior to

73 Simeprevir once a day with peginterferon alfa-2a and ribavirin was well tolerated i

74 , and 900 mg every 12 hours) or placebo plus peginterferon alfa-2a and ribavirin, followed by peginte

75 atment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated

76 chieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin.

77 , or 24 weeks of placebo, each combined with peginterferon alfa-2a and ribavirin.

78 cacy to telaprevir, each in combination with peginterferon alfa-2a and ribavirin.

79 y can achieve SVR following retreatment with peginterferon alfa-2a and ribavirin.

80 nterferon alfa-2a and ribavirin, followed by peginterferon alfa-2a and ribavirin.

81 who were given placebo received 48 weeks of peginterferon alfa-2a and ribavirin.

82 d SVR48 after treatment intensification with peginterferon alfa-2a and ribavirin.

83 t-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.

84 BeAg seroconversion in patients treated with peginterferon alfa-2a and to assess the dynamic changes

85 ht >/=85 kg), a 12-week induction regimen of peginterferon alfa-2a and/or higher-dose ribavirin is no

86 a 2a, and ribavirin was superior to placebo, peginterferon alfa 2a, and ribavirin (SVR12 in 210 [80%]

87 Treatment with simeprevir, peginterferon alfa 2a, and ribavirin was superior to pla

88 mg and 50 received 10 mg of bulevirtide plus peginterferon alfa-2a, and 50 received 10 mg of bulevirt

89 atients treated with regimens that contained peginterferon alfa-2a, and anemia was more common among

90 The combination of nitazoxanide, peginterferon alfa-2a, and ribavirin increased the perce

91 The combination of danoprevir, peginterferon alfa-2a, and ribavirin leads to high rates

92 re randomized to double-blind treatment with peginterferon alfa-2a at 180 or 270 microg/week plus rib

93 conducted a randomized, controlled trial of peginterferon alfa-2a at a dosage of 90 microg per week

94 irin at a dose of 800 to 1400 mg per day, or peginterferon alfa-2a at a dose of 180 microg per week p

95 elaprevir at a dose of 750 mg every 8 hours, peginterferon alfa-2a at a dose of 180 mug per week, and

96 Late responders to peginterferon alfa-2a could also be differentiated from

97 Peginterferon alfa-2a could be an effective therapy for

98 Additional groups included 360 mug/wk peginterferon alfa-2a for 12 weeks then 180 mug/wk pegin

99 o the T24P24 group, receiving telaprevir and peginterferon alfa-2a for 24 weeks (at the same doses as

100 y for 12 weeks followed by nitazoxanide plus peginterferon alfa-2a for 36 weeks (n = 28), or nitazoxa

101 erferon alfa-2a for 12 weeks then 180 mug/wk peginterferon alfa-2a for 36 weeks plus 1200 mg/day riba

102 Three of these groups also received peginterferon alfa-2a for 4, 8, or 12 weeks.

103 Patients were randomized to 180 mug/wk peginterferon alfa-2a for 48 weeks plus 1200 mg/day riba

104 Whether prolonged therapy with peginterferon alfa-2a for 96 weeks and combination thera

105 he treatment trial, 10 patients (30%) in the peginterferon alfa-2a group and 6 (19%) in the untreated

106 e prophylaxis trial, 8 patients (31%) in the peginterferon alfa-2a group and 9 (32%) in the untreated

107 rison was between the 10-mg bulevirtide plus peginterferon alfa-2a group and the 10-mg bulevirtide mo

108 n 46% of those in the 10-mg bulevirtide plus peginterferon alfa-2a group, and in 12% of those in the

109 n 46% of those in the 10-mg bulevirtide plus peginterferon alfa-2a group, and in 12% of those in the

110 s undetectable in 25% of the patients in the peginterferon alfa-2a group, in 26% of those in the 2-mg

111 s undetectable in 17% of the patients in the peginterferon alfa-2a group, in 32% of those in the 2-mg

112 in 32% of those in the 2-mg bulevirtide plus peginterferon alfa-2a group, in 46% of those in the 10-m

113 in 26% of those in the 2-mg bulevirtide plus peginterferon alfa-2a group, in 46% of those in the 10-m

114 Patients given nitazoxanide plus peginterferon alfa-2a had intermediate rates of RVR (54%

115 ecommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for

116 rial--to evaluate the safety and efficacy of peginterferon alfa-2a in patients who had undergone OLT.

117 The strength of peginterferon alfa-2a-induced IFIG response significantl

118 Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as a

119 Overall, 80% of patients received peginterferon alfa-2a monotherapy or peginterferon alfa-

120 either interferon alfa-2a plus ribavirin or peginterferon alfa-2a monotherapy.

121 DUAL 1500 (1500 mg R1626 twice daily [bid] + peginterferon alfa-2a; n = 21); DUAL 3000 (3000 mg R1626

122 -2a; n = 21); DUAL 3000 (3000 mg R1626 bid + peginterferon alfa-2a; n = 32); TRIPLE 1500 (1500 mg R16

123 articipants discontinuing TDF (n = 52, TDF + peginterferon alfa-2a; n = 41, TDF alone), 52 (55.9%) ha

124 tudy medication, consisting of 180 microg of peginterferon alfa-2a once weekly plus daily ribavirin (

125 3/4A protease inhibitor versus placebo, plus peginterferon alfa 2a or 2b plus ribavirin was assessed

126 lacebo group) for 12 weeks, followed by just peginterferon alfa 2a or 2b plus ribavirin.

127 evir group) or placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin (placebo gro

128 Addition of simeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus riba

129 nt with once weekly injections of 180 microg peginterferon alfa-2a or no antiviral treatment for 48 w

130 Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens wer

131 w-dose peginterferon alfa-2b, and 40.9% with peginterferon alfa-2a (P=0.20 for standard-dose vs. low-

132 of combination therapy with bulevirtide and peginterferon alfa-2a, particularly with regard to finit

133 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (placebo group).

134 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (simeprevir group),

135 simeprevir (150 mg once daily, orally) plus peginterferon alfa 2a plus ribavirin for 12 weeks, follo

136 n (simeprevir group), or placebo orally plus peginterferon alfa 2a plus ribavirin for 12 weeks, follo

137 ly, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in tr

138 g the adverse event profiles associated with peginterferon alfa 2a plus ribavirin.

139 r 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily placebo, or 3 million u

140 nfected HBeAg-positive patients who received peginterferon alfa-2a plus oral placebo for 48 weeks.

141 weekly subcutaneous injections of 180 microg peginterferon alfa-2a plus oral ribavirin (1000 mg/d for

142 rin (40 percent vs. 12 percent, P<0.001), or peginterferon alfa-2a plus placebo (40 percent vs. 20 pe

143 group and in 20 (33%) of 61 patients in the peginterferon alfa-2a plus placebo group (odds ratio 1.8

144 rferon alfa-2a plus TDF group and 485 in the peginterferon alfa-2a plus placebo group).

145 erferon alfa-2a plus TDF group and 25 in the peginterferon alfa-2a plus placebo group).

146 eron alfa-2a plus ribavirin, 14 percent with peginterferon alfa-2a plus placebo, and 7 percent with i

147 nterferon alfa-2a plus TDF and 61 to receive peginterferon alfa-2a plus placebo, including 48 (40%) p

148 g per week) plus ribavirin (800 mg per day), peginterferon alfa-2a plus placebo, or interferon alfa-2

149 ve sofosbuvir plus ribavirin for 12 weeks or peginterferon alfa-2a plus ribavirin for 24 weeks.

150 y higher proportion of patients who received peginterferon alfa-2a plus ribavirin had a sustained vir

151 significantly higher among the recipients of peginterferon alfa-2a plus ribavirin than among those as

152 ed with both HIV and HCV, the combination of peginterferon alfa-2a plus ribavirin was significantly m

153 tients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as we

154 ined virologic response were 29 percent with peginterferon alfa-2a plus ribavirin, 14 percent with pe

155 We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b

156 , underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin.

157 We evaluated intensified therapy with peginterferon alfa-2a plus ribavirin.

158 gned 59 HDV RNA-positive patients to receive peginterferon alfa-2a plus TDF and 61 to receive peginte

159 hosis to the two treatment groups (23 in the peginterferon alfa-2a plus TDF group and 25 in the pegin

160 We recorded 944 adverse events (459 in the peginterferon alfa-2a plus TDF group and 485 in the pegi

161 s achieved in 28 (48%) of 59 patients in the peginterferon alfa-2a plus TDF group and in 20 (33%) of

162 and safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo

163 d-dose peginterferon alfa-2b regimen and the peginterferon alfa-2a regimen.

164 erences among the 4 groups or between pooled peginterferon alfa-2a regimens (A + B vs C + D: odds rat

165 bavirin; n = 31); or standard of care (SOC) (peginterferon alfa-2a + ribavirin; n = 20).

166 a; n = 32); TRIPLE 1500 (1500 mg R1626 bid + peginterferon alfa-2a + ribavirin; n = 31); or standard

167 administered for 4 weeks in combination with peginterferon alfa-2a +/- ribavirin in HCV genotype 1-in

168 ct was observed when R1626 was combined with peginterferon alfa-2a +/- ribavirin; up to 74% of patien

169 tional study enrolling patients treated with peginterferon alfa-2a/ribavirin (PEG/RBV) with or withou

170 revir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with ge

171 eceived peginterferon alfa-2a monotherapy or peginterferon alfa-2a/ribavirin combination therapy.

172 f black patients with chronic hepatitis C to peginterferon alfa-2a/ribavirin has demonstrated that tr

173 405 patients treated with mericitabine plus peginterferon alfa-2a/ribavirin in PROPEL and JUMP-C, vi

174 (PR48), combined with a total of 48 weeks of peginterferon alfa-2a/ribavirin.

175 depression was lower in the groups receiving peginterferon alfa-2a than in the group receiving interf

176 nths after completion of a 48-week course of peginterferon alfa-2a These responses remain durable in

177 Peginterferon alfa-2a treated patients had significantly

178 subset, a potential prognostic indicator in peginterferon alfa-2a-treated patients with HIV infectio

179 In conclusion, peginterferon alfa-2a treatment for 48 weeks is safe and

180 The combination of 10-mg bulevirtide plus peginterferon alfa-2a was superior to bulevirtide monoth

181 e randomly assigned to receive 180 microg of peginterferon alfa-2a weekly for 48 weeks, and 67 subjec

182 ck randomisation (1:1) to receive 180 mug of peginterferon alfa-2a weekly plus either TDF (300 mg onc

183 th HCV genotype 2 or 3 to receive 180 mug of peginterferon alfa-2a weekly, plus 800 mg of ribavirin d

184 The safety and efficacy of nitazoxanide plus peginterferon alfa-2a, with or without ribavirin, were e